Edwards Lifesciences

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radiation Therapy Side Effects

Retrieved on: 
Thursday, March 10, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Central Florida, The Company, Twitter, University, Drug development, Physician, Company, Burns, Instagram, Solomon Airlines, Cancer, MD Anderson Cancer Center, Health, Biocuration, Nature, Board, News, Chief Medical Advisor to the President, Nanoparticle, Skin, Sale, Radiation, Doctor of Philosophy, Patient, COVID-19, Survivor, Edwards Lifesciences, Forward-looking statement, LinkedIn, Patent, Medical imaging, Pharmaceutical industry, Facebook

BioCurity, is a preclinical biotech company developing drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.

Key Points: 
  • BioCurity, is a preclinical biotech company developing drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.
  • BioCurity offers the potential to prevent the often-devastating side effects associated with radiation therapy and to enhance the treatment outcomes for patients.
  • BioCurity is a global leader in drug development using cerium oxide nanoparticles to mitigate the side effects associated with radiation therapy.
  • BioCurity is biotech company with a mission to prevent certain short term and long-term side effects of radiation therapy for cancer patients undergoing radiation therapy.

Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis

Retrieved on: 
Wednesday, March 9, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Head, Mucositis, OM, CSR, Incidence, STFU, Clinical study report, Inflammation, Analgesic, Edwards Lifesciences, Kaplan–Meier estimator, Mouth, Homeostasis, Pharynx, 2009 Tour de France, Stage 1 to Stage 11, Patient, KOSDAQ, SOM, AE, Pharmaceutical industry

An iDSMB evaluated the safety endpoint every two weeks in a blinded fashion, until 30 days after the last dosing of Stage 1.

Key Points: 
  • An iDSMB evaluated the safety endpoint every two weeks in a blinded fashion, until 30 days after the last dosing of Stage 1.
  • If a safety issue was noted, the iDSMB was instructed to unblind the treatment assignments to ascertain if the adverse event (AE) was associated with the study drug.
  • Since no safety issues were identified at the end of Stage 1, Stage 2 commenced using 2000 mg of the study drug, consistent with a positive safety outcome.
  • Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases.

Enzychem Lifesciences Announces Formation of Corporate Advisory Committee

Retrieved on: 
Wednesday, March 2, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Harvard School of Dental Medicine, KOSDAQ, Patient, Chemoradiotherapy, Population, Negotiation, CTO, Inflammation, FDA, Columbia University, Drug development, US, Edwards Lifesciences, CEO, Dentistry, Vanderbilt University, Emory University School of Medicine, Clinical trial, Technology transfer, Albert Einstein College of Medicine, Physician, Therapy, Pharmaceutical industry, Medical device

Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee.
  • To reinforce such corporate initiatives, and to start supporting the companys next stage activities, Enzychem has formed the Corporate Advisory Committee.
  • The newly appointed corporate advisors will actively influence the development of strong business strategies to successfully meet corporate objectives.
  • Based on their extensive experience, the corporate advisors will assist Enzychem in accomplishing its business milestones.

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 26, 2022

Retrieved on: 
Wednesday, January 19, 2022
Instagram, Multimedia, Patient, Edwards, NYSE, View, Twitter, Edwards Lifesciences, LinkedIn, YouTube, Critical care, Investor relations, Pharmaceutical industry, Facebook

IRVINE, Calif., Jan. 19, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2021 after the market closes on Wednesday, January 26, 2022, and will host a conference call at 5:00 p.m.

Key Points: 
  • IRVINE, Calif., Jan. 19, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2021 after the market closes on Wednesday, January 26, 2022, and will host a conference call at 5:00 p.m.
  • The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com .
  • Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.
  • Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Retrieved on: 
Wednesday, January 5, 2022
Patient, Webcast, YouTube, NYSE, View, Multimedia, LinkedIn, Edwards, Instagram, Conference, Edwards Lifesciences, Twitter, Critical care, Pharmaceutical industry, Public relations, Facebook

IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate at the J.P. Morgan Healthcare Conference on Monday, January 10, 2022.

Key Points: 
  • IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate at the J.P. Morgan Healthcare Conference on Monday, January 10, 2022.
  • A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://ir.edwards.com/ .
  • Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.
  • Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting

Retrieved on: 
Tuesday, January 4, 2022
Natural killer cell, Clinical trial, Edwards Lifesciences, Research, Company, Patient, Cancer, U.S. Securities and Exchange Commission, Security (finance), Private Securities Litigation Reform Act, Disease, Inflammation, Process control block, NASDAQ, Hospital, Marketing, GLOBE, TNF, Trade, Pharmaceutical industry

Details of the event are as follows:

Key Points: 
  • Details of the event are as follows:
    David Moss, Chief Financial Officer, will participate in a panel discussion at the LifeSci Advisors 11th Annual Corporate Access Event.
  • Please contact your representative at H.C. Wainwright to schedule a virtual one-on-one meeting.
  • INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event

Retrieved on: 
Monday, January 3, 2022
Safety, Standard of care, Diagnosis, Lymphatic system, Cancer, Edwards Lifesciences, Androgen, GU, Travel, Prostate cancer, Survival, Treatment, GLOBE, Company, Ministry of Education (Malaysia), ASCO, Science, CYP17, Therapy, Male, Testosterone, Research, Metastasis, Man, Patient, Tissue, Liver, Symposium, Lymph, Neoplasm, Medical imaging, Life insurance, Pharmaceutical industry

PITTSBORO, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today announced that nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium, which is scheduled to take place in San Francisco, CA from February 17-19, 2022. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer; the recommended phase 2 dose will be selected in Q1 2022 based upon pharmacokinetic, safety, clinical pharmacology, and efficacy results.

Key Points: 
  • The Company also announced that senior management will be available for one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, which is being held virtually from January 5-7, 2022.
  • Investors interested in registering for the event to schedule a meeting with Propella management may click here .
  • GU ASCO received more than 680 abstract submissions, which were reviewed by the Symposium Program Committee.
  • Propella is currently in the Phase 1 portion of a Phase 1/2a program studying its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer.

OptimizeRx to Participate in Panel Presentation at LifeSci Partners Corporate Access Event 2022

Retrieved on: 
Monday, January 3, 2022
Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Company, Organization, Regulation, Patient, Intention, Technology, Forward-looking statement, Edwards Lifesciences

ROCHESTER, Mich., Jan. 03, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced that its chief executive officer, Will Febbo, will moderate the panel “Telehealth & Digital Medicine: At a Crossroads of Virtual Care” at the LifeSci Partners Corporate Access Event, to take place virtually January 5-7, 2022.

Key Points: 
  • OptimizeRxs management team will also be available for one-on-one virtual meetings January 5-7 2022.
  • To schedule a meeting, register at LifeSci Advisors Corporate Access Event 2022 , or contact LifeSci directly by email at [email protected] .
  • These forward-looking statements are based on the Companys current expectations and assumptions regarding the Companys business, the economy, and other future conditions.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Joe Simone, President of Simone Development, Sees Growing Demand for Construction of Life-Sciences Labs

Retrieved on: 
Monday, December 20, 2021
Hospital, NYCEDC, Appetite, Health, Acquisition, Investment, Gold, Economic development, Research, Montefiore Medical Center, Second Industrial Revolution, Edwards Lifesciences, Industrial Revolution, New York City Economic Development Corporation, Albert Einstein College of Medicine, New York Blood Center, Pharmaceutical industry, Montefiore

BRONX, N.Y., Dec. 20, 2021 /PRNewswire-PRWeb/ --Biotech companies' appetite for research institutions' groundbreaking discoveries is driving demand for new life-science facilities, said Joseph Simone of Simone Development Companies.

Key Points: 
  • BRONX, N.Y., Dec. 20, 2021 /PRNewswire-PRWeb/ --Biotech companies' appetite for research institutions' groundbreaking discoveries is driving demand for new life-science facilities, said Joseph Simone of Simone Development Companies.
  • "New York City's university research hospitals are gold mines of innovation and emerging technologies," said Joe Simone.
  • This is just one of several examples of new life-sciences construction proposed throughout the New York metro area," said Joe Simone.
  • Across the street from the proposed biotech facility, Simone Development Companies' Hutchinson Metro Center includes an ambulatory surgical center for Montefiore.

EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT

Retrieved on: 
Monday, December 20, 2021
Forward-looking statement, Instagram, U.S. Securities and Exchange Commission, LinkedIn, Food, FDA, Ventricular septal defect, Securities Exchange Act of 1934, Drug Quality and Security Act, NYSE, Adult, Aortic valve, Tetralogy, Edwards, Securities Act of 1933, Adolescence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TPV, Echocardiography, Patient, Safety, Quality of life, Security (finance), Edwards Lifesciences, Multimedia, Adrenal insufficiency, YouTube, Twitter, Cedars-Sinai Medical Center, Critical care, News, View, Pharmaceutical industry, Medical imaging, Alterra, Facebook

IRVINE, Calif., Dec. 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra) for patients with severe pulmonary regurgitation.

Key Points: 
  • IRVINE, Calif., Dec. 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra) for patients with severe pulmonary regurgitation.
  • The Edwards SAPIEN 3 Transcatheter Pulmonary Valve (TPV) system combines the proven SAPIEN 3 transcatheter heart valve and the Alterra adaptive prestent to expand transcatheter therapy options for congenital heart valve disease patients.
  • The Alterra prestent compensates for variations in size and morphology of the right ventricular outflow tract to provide a stable landing zone for the SAPIEN 3 valve.
  • Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Alterra, SAPIEN and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation.